Abstract
Introduction
Alzheimer's disease (AD) is characterized by a progressive cognitive decline, where memory of recent facts, spatial orientation, attention and executive functions are ones of the first affected. This is followed by speech and behavioural problems, which affect everyday life [1] . The pathological changes in the brain, which define the disease, are abundant extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs), accompanied by synaptic and neuronal loss, and brain inflammation [2] [3] [4] [5] . The amyloid plaques are composed mainly of aggregated amyloid-␤ peptide (A␤) [6, 7] , which is derived by proteolytic cleavage from the amyloid precursor protein (APP) [8] . The A␤ peptide can consist of 39-43 amino acid residues, but the two major forms are A␤40 accounting for ~90% of all A␤ released from cells and the longer A␤42 accounting for only ~10%. A␤42 is more hydrophobic and more prone to aggregation than A␤40 [9] , and is the predominant form found in the amyloid plaques of AD [10] . The NFTs consist of an aggregated form of hyperphosphorylated microtubule-associated protein, tau [11] .
Although the cause of AD still is the subject of considerable debate, the so-called amyloid cascade hypothesis remains the best-defined and most studied conceptual framework for the disease [12] . This hypothesis is based upon the pathological characteristics and the genetics of the disease [13, 14] . To 
The laboratory rat
The rat was the first mammalian species domesticated for scientific research over 180 years ago [16] [31, 32] . Since then different approaches to induce cholinergic lesions in rats have been used to study the role of the cholinergic system in cognitive function [33, 34] 
. The most commonly used neurotoxins included excitatory amino acid neurotransmitters such as glutamate and its analogues (ibotenate, N-methyl-d-aspartate [NMDA], kainate, quisqualate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA])
, the AF64A toxin specific to cholinergic neurons, or muscarinic receptor antagonists scopolamine and atropine [35] . In 1990, a chronic rat model with a continuous intracerebroventricular infusion of quinolinic acid was developed to simulate the slow evolution of neurodegenerative diseases, including AD [36, 37] [32, 43] .
A␤-based models of AD
The discovery that A␤ is the main constituent of the characteristic amyloid plaques in the brains of AD patients [6, 7] and is toxic to neurons [44, 45] [51, [53] [54] [55] [56] [57] , others showed no significant effect of the peptides [58] [59] [60] . Likewise, contradictory results were obtained in similar experiments performed on rhesus monkeys [61, 62] [63] [64] [65] [66] [67] [68] [69] [70] and the deteriorating effects of chronic stress [71] on memory in A␤ injected/infused rats. In 2007, Takata et al. [72] showed that exogenous microglia, transplanted into the brains of rats microinjected with A␤, participate in A␤ clearance.
Recently, a variation on the A␤ infusion model was reported [73] 
Transgenic rats
The first transgenic models of AD, harbouring human APP with FAD-causative mutations, appeared over ten years ago [74, 75] . These models were generated in mouse but simultaneously, unsuccessful attempts were made to develop AD transgenic rats [76, 77] [95, 96] . Although the Tg6590 [105] . 
The UKUR25 rat

The same year as the TgAPPswe rat was reported, a series of papers on double-transgenic Wistar rat line UKUR25 were published [89-92]. The UKUR25 rats express human APP containing the Swedish and Indiana (V717F) mutations, and mutated PS1 (M146L). Both constructs were driven by the PDGF promoter. The main pathological feature in the brain of these animals, visible after 6 months of age, was the accumulation of A␤ intracellularly in neurons of the hippocampus and cortex. The levels of A␤ in the brain has however not been reported. No extracellular amyloid was seen in these animals up to 24 months of age. Behaviour analysis of 7-and 16-month-old UKUR25 rats revealed mild impairment in acquisition learning in 16-month-old male rats. Following acquisition learning the platform was moved and the rats were meant to learn the new location. There was no significant difference between the trangenics and controls in this task. At the age of 9 months, there was an increase in active phospho-ERK2 in the UKUR25 rat brain, which was accompanied by increased levels of tau phosphorylation at S396 and S404 ERK2 sites (recognized by the PHF-1 antibody). The lack of any extracellular pathology together with the mild behavioural phenotype may limit the use of this transgenic rat in AD research.
The Tg6590 rat
Virally induced models of AD
Concluding remarks
The rat is one of the most commonly used experimental animal species in biomedical research and because of its relevance to human physiology, the rat may provide highly predictable models for research and the pharmaceutical industry [108] . 
